Overview
This is a French observational, national, multicenter prospective cohort study of patients with HER2-negative eBC treated with olaparib at their physician's discretion.
Description
The purpose to this observational study is to evaluate the rate of completion of adjuvant Olaparib treatment for HER2-negative early breast cancer patients in France.
Eligibility
Inclusion Criteria:
- Male or female aged ≥ 18 years
- Patient diagnosed with HER2-negative eBC
- Patient about to be initiated with adjuvant Olaparib at their physician's discretion
- Patient has been informed and does not object to participation in the study.
Exclusion Criteria:
- Patient not consenting to participate.
- Patients included in the Early Access Program